Biofield Petitions for Less Burdensome Route For Breast Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Biofield Corp. expects to hear from FDA within 60 days regarding a de novo petition for reclassification of its investigational breast cancer diagnostic device to Class II status
You may also be interested in...
Biofield BDS resolution
"Breast proliferation rate detection system" is Class III, requiring premarket approval, according to FDA, the firm announces March 9. In January, Biofield petitioned for downclassification of the system, which uses electrical signals to evaluate lesions as an adjunct to breast imaging procedures (1"The Gray Sheet" Jan. 17, 2005, p. 38)...
Biofield BDS resolution
"Breast proliferation rate detection system" is Class III, requiring premarket approval, according to FDA, the firm announces March 9. In January, Biofield petitioned for downclassification of the system, which uses electrical signals to evaluate lesions as an adjunct to breast imaging procedures (1"The Gray Sheet" Jan. 17, 2005, p. 38)...
Biofield To Submit Revamped PMA For Breast Cancer Diagnosis System
Biofield is planning to make a second attempt at securing FDA approval for its Biofield Diagnostic Device following the completion of an upcoming clinical trial of the non-invasive tool to evaluate its use as an aid in breast cancer detection.